Want to see RNAC full AI Analyst Report?
RNAC Stock Chart & Stats
$7.88
-$0.09(-1.14%)
At close: 4:00 PM EDT
$7.88
-$0.09(-1.14%)
Day’s Range― - ―
52-Week Range$5.60 - $11.80
Previous Close$7.79
Volume79.05K
Average Volume (3M)250.94K
Market Cap
$267.46M
Enterprise Value$227.40
Total Cash (Recent Filing)$147.61M
Total Debt (Recent Filing)$63.85M
Price to Earnings (P/E)―
Beta2.85
Next Earnings
Nov 05, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.93
Shares Outstanding30,255,352
10 Day Avg. Volume146,274
30 Day Avg. Volume250,943
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-1.48
Price to Sales (P/S)66.95
P/FCF Ratio-2.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.83Price Target Upside329.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.98
Revenue Forecast (FY)$382.00K
Bulls Say, Bears Say
Bulls Say
Strategic Licensing Alliance (in Vivo CAR‑T)The WestGene alliance structurally shifts Cartesian toward in vivo CAR‑T delivery, potentially removing complex ex‑vivo manufacturing steps. That could materially lower development complexity and cost, speed time‑to‑patient, and strengthen long‑term competitive positioning in autoimmune cell therapies.
Material Non‑dilutive Financing Extends RunwayThe up‑to‑$150M secured facility provides multi‑year financing without immediate equity dilution, enabling completion of pivotal trials and a planned BLA. This reduces near‑term funding risk, allows execution of development milestones, and preserves optionality for strategic choices over the next 2–3 years.
Governance And Oversight ContinuityStrong shareholder support for directors and the reappointment of a Big Four auditor indicates governance stability and continuity in financial oversight. Stable board and audit arrangements reduce execution and reporting risk during critical late‑stage development and regulatory milestones.
Bears Say
Collapsed And Volatile RevenueRevenue has contracted dramatically and unpredictably over multiple years, signaling weak near‑term commercial traction and a reliance on R&D progress rather than product sales. Sustained low revenue undermines internal funding capacity and increases long‑term dependence on external capital to advance programs.
Persistent Negative Cash Flow / Cash BurnContinuous negative operating and free cash flow indicate the company must rely on financing to sustain operations. Even with the loan facility, ongoing burn constrains strategic flexibility, risks future dilution or higher borrowing costs, and makes execution vulnerable if clinical timelines slip.
Negative Equity And Constrained Balance‑sheet FlexibilityDeeply negative equity reflects accumulated losses and limits traditional financing options. This reduces strategic optionality, weakens creditor and partner negotiating positions, and raises the likelihood that future growth will require dilutive equity or secured financing, impairing long‑term financial resilience.
Cartesian Therapeutics News
RNAC FAQ
What was Cartesian Therapeutics, Inc.’s price range in the past 12 months?
Cartesian Therapeutics, Inc. lowest stock price was $5.60 and its highest was $11.80 in the past 12 months.
What is Cartesian Therapeutics, Inc.’s market cap?
Cartesian Therapeutics, Inc.’s market cap is $267.46M.
When is Cartesian Therapeutics, Inc.’s upcoming earnings report date?
Cartesian Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 80 days.
How were Cartesian Therapeutics, Inc.’s earnings last quarter?
Cartesian Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of -$0.878 by $1.338.
Is Cartesian Therapeutics, Inc. overvalued?
According to Wall Street analysts Cartesian Therapeutics, Inc.’s price is currently Undervalued.
Does Cartesian Therapeutics, Inc. pay dividends?
Cartesian Therapeutics, Inc. does not currently pay dividends.
What is Cartesian Therapeutics, Inc.’s EPS estimate?
Cartesian Therapeutics, Inc.’s EPS estimate is -1.01.
How many shares outstanding does Cartesian Therapeutics, Inc. have?
Cartesian Therapeutics, Inc. has 30,255,352 shares outstanding.
What happened to Cartesian Therapeutics, Inc.’s price movement after its last earnings report?
Cartesian Therapeutics, Inc. reported an EPS of $0.46 in its last earnings report, beating expectations of -$0.878. Following the earnings report the stock price went up 4.91%.
Which hedge fund is a major shareholder of Cartesian Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RNAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cartesian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.83 (329.36% Upside)
$33.83 (329.36% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 22.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-41.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.07%
Trailing 12-Months
Company Description
Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
RNAC Stock 12 Month Forecast
Average Price Target
$33.83
▲(329.36% Upside)
Technical Analysis
Puma Biotechnology
―
DBV Technologies SA - American
―
Voyager Therapeutics
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Ownership Overview
42.90% Insiders
7.11% Mutual Funds
4.10% Other Institutional Investors
41.13% Public Companies and
Individual Investors